Aducanumab: a new phase in therapeutic development for Alzheimer’s disease? | Zendy

Lalli Giovanna | Zendy; Schott Jonathan M | Zendy; Hardy John | Zendy; De Strooper Bart | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Aducanumab: a new phase in therapeutic development for Alzheimer’s disease?

Author(s) -

Lalli Giovanna,

Schott Jonathan M,

Hardy John,

De Strooper Bart

Publication year - 2021

Publication title -

embo molecular medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.923

H-Index - 107

eISSN - 1757-4684

pISSN - 1757-4676

DOI - 10.15252/emmm.202114781

Subject(s) - disease , drug development , drug , medicine , alzheimer's disease , mechanism (biology) , drug discovery , amyloid (mycology) , pharmacology , bioinformatics , pathology , biology , philosophy , epistemology

On 7 June , the FDA approved aducanumab, the first new drug for Alzheimer’s disease in almost 20 years—and notably, the first drug with a putative disease‐modifying mechanism for the treatment of this devastating disorder, namely the removal of β‐amyloid (or Aβ) plaques from the brain.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research